Northland Capital slashes price target on Ironwood Pharmaceuticals Inc. [IRWD] – find out why.

Ironwood Pharmaceuticals Inc. [NASDAQ: IRWD] loss -2.65% or -0.25 points to close at $9.17 with a heavy trading volume of 4678649 shares. The company report on July 23, 2020 that Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2020 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2020. Individuals interested in participating in the call should dial (866) 324-3683 (U.S. and Canada) or (509) 844-0959 (international) using conference ID number and event passcode 6183913. To access the webcast, please visit the Investors section of Ironwood’s website at at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting Thursday, August 6, 2020 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on August 20, 2020. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 6183913. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.

It opened the trading session at $9.41, the shares rose to $9.44 and dropped to $8.71, the range by which the price of stock traded the whole day. The daily chart for IRWD points out that the company has recorded -24.09% loss over the past six months. However, it is still -15.93% lower than its most recent low trading price.

If we look at the average trading volume of 2.20M shares, IRWD reached to a volume of 4678649 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Ironwood Pharmaceuticals Inc. [IRWD]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IRWD shares is $12.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IRWD stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Northland Capital have made an estimate for Ironwood Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 17, 2020. The new note on the price target was released on July 10, 2019, representing the official price target for Ironwood Pharmaceuticals Inc. stock.

The Average True Range (ATR) for Ironwood Pharmaceuticals Inc. is set at 0.42, with the Price to Sales ratio for IRWD stock in the period of the last 12 months amounting to 3.42. Price to Free Cash Flow for IRWD in the course of the last twelve months was 16.44 with Quick ratio for the last quarter at 12.10.

Trading performance analysis for IRWD stock

Ironwood Pharmaceuticals Inc. [IRWD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.58. With this latest performance, IRWD shares dropped by -9.83% in over the last four-week period, additionally sinking by -24.09% over the last 6 months – not to mention a drop of -11.06% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IRWD stock in for the last two-week period is set at 38.85, with the RSI for the last a single of trading hit 35.16, and the three-weeks RSI is set at 41.46 for Ironwood Pharmaceuticals Inc. [IRWD]. The present Moving Average for the last 50 days of trading for this stock 10.04, while it was recorded at 9.36 for the last single week of trading, and 11.02 for the last 200 days.

Ironwood Pharmaceuticals Inc. [IRWD]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Ironwood Pharmaceuticals Inc. [IRWD] shares currently have an operating margin of +27.32 and a Gross Margin at +93.12. Ironwood Pharmaceuticals Inc.’s Net Margin is presently recorded at +13.76.

Return on Total Capital for IRWD is now 42.14, given the latest momentum, and Return on Invested Capital for the company is 23.26. Additionally, IRWD Total Debt to Total Capital is recorded at 127.59, with Total Debt to Total Assets ending up at 107.07.

Reflecting on the efficiency of the workforce at the company, Ironwood Pharmaceuticals Inc. [IRWD] managed to generate an average of $185,940 per employee. Receivables Turnover for the company is 4.32 with a Total Asset Turnover recorded at a value of 1.17.Ironwood Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.10 and a Current Ratio set at 12.10.

Ironwood Pharmaceuticals Inc. [IRWD]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Ironwood Pharmaceuticals Inc. posted 0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.03/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 433.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IRWD.

An analysis of insider ownership at Ironwood Pharmaceuticals Inc. [IRWD]

There are presently around $1,638 million, in the hands of institutional investors. The top three institutional holders of IRWD stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 22,064,270, which is approximately 1.568% of the company’s market cap and around 2.00% of the total institutional ownership; BROWN CAPITAL MANAGEMENT LLC, holding 17,960,849 shares of the stock with an approximate value of $164.7 million in IRWD stocks shares; and VANGUARD GROUP INC, currently with $149.85 million in IRWD stock with ownership of nearly -1.789% of the company’s market capitalization.

Positions in Ironwood Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 95 institutional holders increased their position in Ironwood Pharmaceuticals Inc. [NASDAQ:IRWD] by around 18,431,460 shares. Additionally, 99 investors decreased positions by around 16,682,466 shares, while 32 investors held positions by with 143,543,107 shares. The mentioned changes placed institutional holdings at 178,657,033 shares, according to the latest SEC report filing. IRWD stock had 27 new institutional investments in for a total of 5,965,936 shares, while 31 institutional investors sold positions of 2,056,506 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam